Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Debt to Equity (2016 - 2025)

Historic Debt to Equity for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $0.89.

  • BioRestorative Therapies' Debt to Equity rose 15788.95% to $0.89 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.89, marking a year-over-year increase of 15788.95%. This contributed to the annual value of $0.3 for FY2024, which is 1291.23% up from last year.
  • Latest data reveals that BioRestorative Therapies reported Debt to Equity of $0.89 as of Q3 2025, which was up 15788.95% from $0.53 recorded in Q2 2025.
  • BioRestorative Therapies' Debt to Equity's 5-year high stood at $3.69 during Q2 2023, with a 5-year trough of -$1.67 in Q1 2021.
  • For the 5-year period, BioRestorative Therapies' Debt to Equity averaged around $0.45, with its median value being $0.42 (2024).
  • Its Debt to Equity has fluctuated over the past 5 years, first plummeted by 56806.34% in 2021, then surged by 366436.74% in 2022.
  • Over the past 5 years, BioRestorative Therapies' Debt to Equity (Quarter) stood at $0.01 in 2021, then surged by 3664.37% to $0.54 in 2022, then crashed by 51.41% to $0.26 in 2023, then increased by 12.91% to $0.3 in 2024, then soared by 201.83% to $0.89 in 2025.
  • Its last three reported values are $0.89 in Q3 2025, $0.53 for Q2 2025, and $0.51 during Q1 2025.